As of 2026-04-26, the EV/EBITDA ratio of Fulcrum Therapeutics Inc (FULC) is -6.24. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FULC's latest enterprise value is 324.61 mil USD. FULC's TTM EBITDA according to its financial statements is -52.05 mil USD. Dividing these 2 quantities gives us the above FULC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-04-23 | -6.54 |
| 2026-04-22 | -6.12 |
| 2026-04-21 | -5.84 |
| 2026-04-20 | -6.36 |
| 2026-04-17 | -6.81 |
| 2026-04-16 | -6.43 |
| 2026-04-15 | -6.76 |
| 2026-04-14 | -6.31 |
| 2026-04-13 | -6.10 |
| 2026-04-10 | -5.87 |
| 2026-04-09 | -6.33 |
| 2026-04-08 | -6.31 |
| 2026-04-07 | -6.22 |
| 2026-04-06 | -6.22 |
| 2026-04-02 | -6.49 |
| 2026-04-01 | -5.78 |
| 2026-03-31 | -6.02 |
| 2026-03-30 | -4.62 |
| 2026-03-27 | -4.82 |
| 2026-03-26 | -5.09 |
| 2026-03-25 | -5.14 |
| 2026-03-24 | -4.78 |
| 2026-03-23 | -5.02 |
| 2026-03-20 | -4.87 |
| 2026-03-19 | -5.21 |
| 2026-03-18 | -5.06 |
| 2026-03-17 | -5.71 |
| 2026-03-16 | -5.73 |
| 2026-03-13 | -5.99 |
| 2026-03-12 | -5.97 |
| 2026-03-11 | -6.17 |
| 2026-03-10 | -6.45 |
| 2026-03-09 | -6.36 |
| 2026-03-06 | -6.66 |
| 2026-03-05 | -6.65 |
| 2026-03-04 | -6.89 |
| 2026-03-03 | -6.28 |
| 2026-03-02 | -6.20 |
| 2026-02-27 | -6.93 |
| 2026-02-26 | -7.38 |
| 2026-02-25 | -7.70 |
| 2026-02-24 | -7.18 |
| 2026-02-23 | -10.14 |
| 2026-02-20 | -10.28 |
| 2026-02-19 | -11.21 |
| 2026-02-18 | -10.20 |
| 2026-02-17 | -9.85 |
| 2026-02-13 | -9.81 |
| 2026-02-12 | -10.10 |
| 2026-02-11 | -10.11 |